Panobinostat
 |
|
| Clinical data | |
|---|---|
| Trade names | Farydak |
| AHFS/Drugs.com | farydak |
| Routes of administration |
By mouth (capsules) |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 21% |
| Protein binding | 90% |
| Metabolism | CYP3A (40%), CYP2D6, CYP2C19 |
| Biological half-life | 37 hours |
| Excretion | Fecal (44–77%), renal (29–51%) |
| Identifiers | |
|
|
| Synonyms | LBH-589 |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ECHA InfoCard | 100.230.582 |
| Chemical and physical data | |
| Formula | C21H23N3O2 |
| Molar mass | 349.42622 g/mol |
| 3D model (Jmol) | |
|
|
|
|
  (what is this?)
|
|
Panobinostat (trade name Farydak FAYR-ah-dak) is a drug by Novartis for the treatment of various cancers. It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor).
On 23 February 2015 it received FDA accelerated approval for use in patients with multiple myeloma, and on 28 August 2015 it was approved by the European Medicines Agency for the same use.
Panobinostat is used in combination with the anti-cancer drug bortezomib and the corticoid dexamethasone for the treatment of multiple myeloma in adults who had received at least two previous treatments, including bortezomib and an immunomodulatory agent.
The drug is contraindicated in nursing mothers. To judge from experiments in animals, there is a risk for the unborn child if used during pregnancy; still, the benefit of panobinostat may outweigh this risk.
Common side effects (in more than 10% of patients) include low blood cell counts (pancytopenia, thrombocytopenia, anaemia, leucopenia, neutropenia, lymphopenia), airway infections, as well as unspecific reactions such as fatigue, diarrhoea, nausea, headache, and sleeping problems.
Panobinostat inhibits multiple histone deacetylase enzymes, a mechanism leading to apoptosis of malignant cells via multiple pathways.
...
Wikipedia